197 related articles for article (PubMed ID: 11345654)
41. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
Liu L; Markowitz S; Gerson SL
Cancer Res; 1996 Dec; 56(23):5375-9. PubMed ID: 8968088
[TBL] [Abstract][Full Text] [Related]
42. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors.
Boulton S; Pemberton LC; Porteous JK; Curtin NJ; Griffin RJ; Golding BT; Durkacz BW
Br J Cancer; 1995 Oct; 72(4):849-56. PubMed ID: 7547230
[TBL] [Abstract][Full Text] [Related]
43. 4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer.
Schlicker A; Peschke P; Bürkle A; Hahn EW; Kim JH
Int J Radiat Biol; 1999 Jan; 75(1):91-100. PubMed ID: 9972795
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Tentori L; Leonetti C; Scarsella M; Muzi A; Mazzon E; Vergati M; Forini O; Lapidus R; Xu W; Dorio AS; Zhang J; Cuzzocrea S; Graziani G
FASEB J; 2006 Aug; 20(10):1709-11. PubMed ID: 16809434
[TBL] [Abstract][Full Text] [Related]
45. PARP inhibitors stumble in breast cancer.
Guha M
Nat Biotechnol; 2011 May; 29(5):373-4. PubMed ID: 21552220
[No Abstract] [Full Text] [Related]
46. Poly(ADP-ribose) polymerase-1 protects excessive DNA strand breaks from deterioration during repair in human cell extracts.
Parsons JL; Dianova II; Allinson SL; Dianov GL
FEBS J; 2005 Apr; 272(8):2012-21. PubMed ID: 15819892
[TBL] [Abstract][Full Text] [Related]
47. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Liu X; Shi Y; Maag DX; Palma JP; Patterson MJ; Ellis PA; Surber BW; Ready DB; Soni NB; Ladror US; Xu AJ; Iyer R; Harlan JE; Solomon LR; Donawho CK; Penning TD; Johnson EF; Shoemaker AR
Clin Cancer Res; 2012 Jan; 18(2):510-23. PubMed ID: 22128301
[TBL] [Abstract][Full Text] [Related]
48. Triazene compounds: mechanism of action and related DNA repair systems.
Marchesi F; Turriziani M; Tortorelli G; Avvisati G; Torino F; De Vecchis L
Pharmacol Res; 2007 Oct; 56(4):275-87. PubMed ID: 17897837
[TBL] [Abstract][Full Text] [Related]
49. Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
Chen M; Osman I; Orlow SJ
Mol Cancer Res; 2009 May; 7(5):703-12. PubMed ID: 19435820
[TBL] [Abstract][Full Text] [Related]
50. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
[TBL] [Abstract][Full Text] [Related]
51. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide.
Fishel ML; He Y; Smith ML; Kelley MR
Clin Cancer Res; 2007 Jan; 13(1):260-7. PubMed ID: 17200364
[TBL] [Abstract][Full Text] [Related]
52. Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints.
Sabisz M; Wesierska-Gadek J; Skladanowski A
Biochem Pharmacol; 2010 May; 79(10):1387-97. PubMed ID: 20067769
[TBL] [Abstract][Full Text] [Related]
53. Low nicotinamide mononucleotide adenylyltransferase activity in a tiazofurin-resistant cell line: effects on NAD metabolism and DNA repair.
Boulton S; Kyle S; Durkacz BW
Br J Cancer; 1997; 76(7):845-51. PubMed ID: 9328141
[TBL] [Abstract][Full Text] [Related]
54. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
55. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
McEllin B; Camacho CV; Mukherjee B; Hahm B; Tomimatsu N; Bachoo RM; Burma S
Cancer Res; 2010 Jul; 70(13):5457-64. PubMed ID: 20530668
[TBL] [Abstract][Full Text] [Related]
56. Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells.
D'Atri S; Graziani G; Lacal PM; Nisticò V; Gilberti S; Faraoni I; Watson AJ; Bonmassar E; Margison GP
J Pharmacol Exp Ther; 2000 Aug; 294(2):664-71. PubMed ID: 10900246
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of poly(ADP-ribose)polymerase-1 and DNA repair by uranium.
Cooper KL; Dashner EJ; Tsosie R; Cho YM; Lewis J; Hudson LG
Toxicol Appl Pharmacol; 2016 Jan; 291():13-20. PubMed ID: 26627003
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
Bryant HE; Helleday T
Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
[TBL] [Abstract][Full Text] [Related]
59. Induction of ROS formation, poly(ADP-ribose) polymerase-1 activation, and cell death by PCB126 and PCB153 in human T47D and MDA-MB-231 breast cancer cells.
Lin CH; Lin PH
Chem Biol Interact; 2006 Aug; 162(2):181-94. PubMed ID: 16884709
[TBL] [Abstract][Full Text] [Related]
60. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.
Skalitzky DJ; Marakovits JT; Maegley KA; Ekker A; Yu XH; Hostomsky Z; Webber SE; Eastman BW; Almassy R; Li J; Curtin NJ; Newell DR; Calvert AH; Griffin RJ; Golding BT
J Med Chem; 2003 Jan; 46(2):210-3. PubMed ID: 12519059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
